Drug Profile
Efavirenz/lamivudine/tenofovir disoproxil fumarate - Viatris
Alternative Names: 3TC/EFV/TDF; Avonza; Efavirenz 400mg/lamivudine 300mg/tenofovir disoproxil fumarate 300mg; Efavirenz 600mg/lamivudine 300mg/tenofovir disoproxil fumarate 300mg; Efavirenz/tenofovir disoproxil fumarate/lamivudine; EFV/3TC/TDF; EFV/TDF/3TC; Lamivudine/efavirenz/tenofovir disoproxil fumarate; Lamivudine/tenofovir disoproxil fumarate/efavirenz; Symfi; Symfi Lo; TDF/3TC/EFV; Telura; Tenofovir disoproxil fumarate/efavirenz/lamivudine; TLE 400Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Matrix Laboratories
- Developer The HIV Netherlands Australia Thailand Research Collaboration; Viatris Inc
- Class Alkynes; Antiretrovirals; Benzoxazines; Cyclopropanes; Deoxyribonucleosides; Dideoxynucleosides; Phosphonic acids; Purines; Pyrimidine nucleosides
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed HIV-1 infections
Most Recent Events
- 28 Mar 2018 Mylan intends to launch efavirenz/lamivudine/tenofovir disoproxil fumarate (600mg/300mg/300mg) in USA in second quarter of 2018
- 22 Mar 2018 Registered for HIV-1 infections (In adolescents, In children, In adults) in USA (PO)
- 02 Mar 2018 Mylan intends to launch efavirenz/lamivudine/tenofovir disoproxil fumarate in USA in March 2018